CC

The Chemours Company

Fundamental data last updated:October 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Basic Materials

industry

Chemicals - Specialty

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.

 


VALUATION

P/E

-8.31

Market Cap ($M USD)

$3.42B

Forward P/E

8.40

PEG

0.04

PRICE TO SALES

0.59

PRICE TO BOOK

15.89

EV / EBITDA

42.62

5-Year Average P/E

Free Cash Flow Yield

4.51%

DCF Value

$6.07

Graham Number

N/A

Price to FCF

22.19

EV to FCF

47.04

Earnings Yield

-12.03%

FCF Yield

4.51%

DIVIDEND

Yield

1.54%

Annual Payout

$0.35

Payout Ratio

-13.14%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.73

Next Year EPS Growth Estimate

$2.71

Next Year Revenue Growth Estimate

$6.68B

Return on Equity (ROE)

-164.40%

FREE CASH FLOW

Operating Margin

-0.33%

Debt-to-Equity

18.34

Piotroski F-Score

3

Altman Z-Score

1.60

Return on Invested Capital (ROIC)

-0.34%

Current Ratio

1.82

Quick Ratio

0.87

Net Debt to EBITDA

22.52

Interest Coverage

-0.07

Gross Profit margin

15.13%

FCF PER SHARE

$1.02

REVENUE PER SHARE

$38.72

Gainseekers Quantitative Analysis

Summary

The Chemours Company presents a perplexing valuation scenario. Despite a forward P/E of 8.47 suggesting potential value, the current negative P/E and earnings yield indicate significant past struggles. The Altman Z-score of 1.62 raises red flags about financial distress, while the DCF value starkly contrasts with recent pricing, hinting at overvaluation. The market seems to be pricing in a turnaround, but the negative ROIC and operating margins suggest execution risks remain high. Investors should tread carefully, as the stock appears mispriced relative to its intrinsic value.

AI Exposure / Tech Reliance

Operating in the Chemicals - Specialty industry, Chemours is positioned to leverage AI for process optimization and supply chain efficiencies. However, the sector's capital-intensive nature may slow tech adoption. Its resilience will depend on integrating AI into core operations to enhance productivity.

The Bull Case

For the optimistic investor, Chemours offers a tantalizing prospect with a forward PEG ratio of 0.04, indicating potential undervaluation relative to growth. The FCF yield of 4.44% suggests some cash flow strength, while a Piotroski F-Score of 3 hints at moderate financial health. Despite negative margins, the company’s ability to generate free cash flow could signal underlying pricing power and operational efficiency, appealing to those seeking a turnaround story.

The Bear Case

Chemours faces daunting structural challenges. The negative return on equity of -164.40% and a staggering debt/equity ratio of 18.34 highlight severe financial strain. The price/book ratio of 16.11 and EV/EBITDA of 42.90 suggest the stock is priced for perfection, despite its precarious financial footing. With a net debt to EBITDA ratio of 22.52, liquidity concerns loom large, making it a risky proposition near its 52-week high.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$25.75

Institutional Ownership %

1-Year Beta

1.46

Insider Buying % (6 Mo)

Distance to 52-Week High

26.19%

Distance to 52-Week Low

59.82%

EARNINGS SURPRISE %

200.00%

50-DAY SMA

$23.01

200-DAY SMA

$16.91

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.